TRIPASS XR تري باس

Cui Y et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of

phase III trials. Int Urol Nephrol. 2014;46(1):275–284.

Chapple CR et al. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an

overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol. 2014;21(10):960–967.

Myrbetriq [product information]. Northbrook, IL; Astellas Pharma; 2014.

Sink KM et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and

cognitive outcomes. J Am Geriatr Soc. 2008;56:847.

Castleden CM et al. Imipramine—a possible alternative to current therapy for urinary incontinence in the elderly.

J Urol. 1981;125:318.

Hollister LE. Current antidepressants. Annu Rev Pharmacol Toxicol. 1986;26:23.

Levin RM et al. Analysis of the anticholinergic and musculotropic effects of desmethylimipramine on the rabbit

urinary bladder. Urol Res. 1983;11:259.

Wein AJ, Barrett DM. Peripheral innervation of the lower urinary tract. In: Marshall DK, ed. Voiding Function

and Dysfunction: A Logical and Practical Approach. Chicago, IL: Year Book Medical Publishers; 1988.

Mariappan P et al. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress

urinary incontinence: a systematic review. Eur Urol. 2007;51:67.

Gibson A. The influence of endocrine hormones on the autonomic nervous system. J Auton Pharmacol.

1981;1:331.

Batra SC, Iosif CS. Female urethra: a target for estrogen action. J Urol. 1983;129:418.

Lepor H, Theune C. Randomized double-blind study comparing the efficacy of terazosin versus placebo in women

with prostatism-like symptoms. J Urol. 1995;154:116.

Hajebrahimi S et al. Effect of tamsulosin versus prazosin on clinical and urodynamic parameters in women with

voiding difficulty: a randomized clinical trial. Int J Gen Med. 2011;4:35.

Walsh PC. Benign prostatic hyperplasia. In: Walsh PC et al, eds. Campbell’s Textbook of Urology. 5th ed. Vol.

2. Philadelphia, PA: WB Saunders; 1986:1248.

Strandberg JD. Comparative pathology of benign prostatic hypertrophy. In: Lepor H, Lawson RK, eds. Prostatic

Diseases. Philadelphia, PA: WB Saunders; 1993:399.

Berry SJ et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474.

Narayan P. Neoplasms of the prostate. In: Tanagho E, McAninch J, eds. Smith’s General Urology. 13th ed. East

Norwalk, CT: Appleton & Lange; 1992:165.

Greenwald P et al. Cancer of the prostate among men with benign prostatic hyperplasia. J Natl Cancer Inst.

1974;53:335.

Takahashi S et al. Latent prostatic carcinomas found at autopsy in men over 90 years old. Jpn J Clin Oncol.

1992;22:117.

Issacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 1989;2:33.

Lepor H. Medical therapy for benign prostatic hyperplasia. Urology. 1993;42:483.

Bartsch G et al. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign hyperplasia. Eur

Urol. 2000;37:367.

Hiramatsu M et al. Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and

carcinoma. Histopathology. 1996;28:163.

Boyarsky S et al. A new look at bladder neck obstruction by the Food and Drug Administration regulators:

guidelines for the investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg. 1977;68:29.

Barry MJ et al. The American Urological Association symptom index for benign prostatic hyperplasia. The

Measurement Committee of the American Urological Association. J Urol. 1992;148:1549.

Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and

seventy-nine years of age. Urology. 1993;42:36.

Litwin MS et al. The National Institutes of Health chronic prostatitis symptom index: development and validation

of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol. 1999;162:369.

DuBeau CE, Resnick NM. Controversies in the diagnosis and management of benign prostatic hypertrophy. Adv

Intern Med. 1992;37:55.

Dalkin BL et al. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic

carcinoma. J Urol. 1993;150:1837.

Reissigl A et al. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer:

results of a large screening study. Urology. 1995;46:662.

Borer JG et al. Age specific prostate-specific antigen reference ranges: population specific. J Urol. 1998;159:444.

Slovacek KJ et al. Use of age-specific normal ranges for serum prostate-specific antigen. Arch Pathol Lab Med.

1998;122:330.

Richardson TD, Oesterling JE. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin

North Am. 1997;24:339.

Ravel R. Laboratory aspects of cancer. In: Ravel R, ed. Clinical Laboratory Medicine: Clinical Applications of

Laboratory Data. 6th ed. St Louis, MO: CV Mosby; 1995:555.

Fulton B et al. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and

benign hyperplasia [published corrections appear in Drugs. 1995;49:554; Drugs. 1995;50:559]. Drugs.

1995;49:295.

Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J

Urol. 2003;169:1520.

Pool JL. Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Br J Clin Pract.

1996;50:154.

Chapple CR et al. Tamsulosin, the first prostate-selective alpha-1A-adenoceptor antagonist. A meta-analysis of

two randomized, placebo-controlled, multicentre studies inpatients with benign prostatic obstruction

(symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29:155.

Murayama K et al. Clinical evaluation of tamsulosin hydrochloride on bladder outlet obstruction associated with

benign prostatic hyperplasia; effect on urethral pressure profile and cystometrogram [in Japanese]. Hinyokika

Kiyo. 1997;43:799.

Kamimura H et al. Identification of cytochrome P450 involved in metabolism of the alpha1-adrenoceptor blocker

tamsulosin in human liver microsomes. Xenobiotica. 1998;28:909.

Wolzt M et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal

function: an open-labelsingle-dose and multiple-dose study. Eur J Clin Pharmacol. 1998;54:367.

Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

normal volunteers. J Urol. 2006;176(4, pt 1):1529–1533.

Narayan P. Tamsulosin: the United States trials. Geriatrics. 1998;53(Suppl 2):S29.

Murata S et al. Tissue selectivity of KMD-3213, an alpha(1)adrenoreceptor antagonist, in human prostate and

vasculature. J Urol. 2000;164:578.

Yu HJ et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms

(LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int. 2011;108(11):1843–1848.

Marks LS et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with

signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol.

2009;181(6):2634.

Isaacs JT et al. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. J Clin

Endocrinol Metab. 1983;56:139.

Matzkin H, Braf Z. Endocrine treatment of benign prostatic hypertrophy: current concepts. Urology. 1991;37:1.

Wilson JP. The pathogenesis of benignprostatichyperplasia. Am J Med. 1980;68:745.

Bartsh W et al. Hormone blood levels and their interrelationships in normal men and men with benign prostatic

hypertrophy (BPH). Acta Endocrinol (Copenh). 1979;90:727.

Ghanadian R et al. Serum dihydrotestosterone in patients with benign prostatic hypertrophy. Br J Urol.

1977;49:541.

Siiteri PK, Wilson JD. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of

dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest. 1970;49:1737.

Bruchovsky N, Lieskovsky G. Increased ration of 5 alphareductase: 3 alpha (beta)-hydroxysteroid dehydrogenase

activities in the hyperplastic human prostate. J Endocrinol. 1979;80:289.

Habenicht UF et al. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog

and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results. Prostate.

1986;8:181.

Geller J, Albert JD. BPH and prostate cancer: results of hormonal manipulation. In: Bruchovsky N et al, eds.

Regulation of Androgen Action. Berlin, Germany: Conrgessdruck R. Bruckner; 1985:37.

Charisiri N, Pierrepoint CG. Examination of the distribution of oestrogen receptor between the stromal and

epithelial compartments of the canine prostate. Prostate. 1980;1:357.

Feldman HA et al. Impotence and its psychosocial correlates: results of the Massachusetts Male Aging Study. J

Urol. 1994;151:54.

DeKlerk DP et al. Comparison of spontaneous and experimentally induced canine prostatic hypertrophy. J Clin

Invest. 1979;64:842.

McConnell JD et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in

men 3 with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74:505.

Lowe FC et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia.

Urology. 2003;61:791.

Gormley GJ et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study

Group. N EnglJ Med. 1992;327:1185.

Stoner E et al. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign

prostatic hyperplasia. The Finasteride Study Group. Arch Intern Med. 1994;154:83.

Weeslls H et al. Incidence and severity of sexual adverse prostatic hyperplasia. Urology. 2003;61:579.

Abrams P et al. Improvement of pressure flow parameters with finasteride is greater in men with large

prostates. Finasteride Urodynamics Study Group. Urology. 1999;161:1513.

[No authors listed]. Finasteride for benign prostatic hypertrophy. Med Lett Drugs Ther. 1992;34:83.

[No authors listed]. One year experience in the treatment of benign prostatic hyperplasia with finasteride. The

MK-906 (Finasteride) Study Group. J Androl. 1991;12:372.

Yang XJ et al. Does long-term finasteride therapy affect the histological features of benign prostatic tissue and

prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.

Urology. 1999;53:696.

Montironi R et al. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological

changes in patients who fail to respond. J Clin Pathol. 1996;49:324.

Roehrborn CG et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in

men with benign prostatic hyperplasia. Urology. 2002;60:434.

McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical

progression of benign prostatic hyperplasia. N Eng J Med. 2003;349:2387.

.

.

.

.

.

120.

121.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Roehrborn CG et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in

men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study [published

correction appears in Eur Urol. 2010;58:801]. Eur Urol. 2010;57:123.

Keane PF et al. Response of the benign hypertrophied prostate to treatment with an LHRH analogue. Br J Urol.

1988;62:163.

Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for

adenocarcinoma of the prostate. J Urol. 1991;145:907.

Guess HA et al. The effect of finasteride on prostate specific antigen in men with benign prostatic hyperplasia.

Prostate. 1993;22:31.

Wilt TJ et al. Sawpalmetto extracts for treatment of benign prostatic hyperplasia: a systematic review [published

correction appears in JAMA. 1999;281:515]. JAMA. 1998;280:1604.

Bent S et al. Saw palmetto for benign prostatic hyperplasia. N Eng J Med. 2006;354:557.

Bayne CW et al. Serenoa repens (Permixon): a 5alphareductase types I and II inhibitor—new evidence in a

coculture model of BPH. Prostate. 1999;40:232.

Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician. 2003;67:1281.

Carraro JC et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate

hyperplasia: a randomized internationalstudy of 1,098 patients. Prostate. 1996;29:231.

Tacklind J et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev.

2012;12:CD001423.

Wilt T et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev.

2002(1):CD001044.

American Urological Association. Clinical guideline on the management of BPH (2010 update).

http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(2010-reviewed-and-validityconfirmed-2014). Accessed June 18, 2015.

Bruskewitz RC, Christensen MM. Critical evaluation of transurethral resection and incision of the prostate.

Prostate. 1990;3:27.

Fowler FJ, Jr et al. Symptom status and quality of life following prostatectomy. JAMA. 1988;259:3018.

Lindau ST, Gavrilova N. Sex, health, and years of sexually active life gained due to good health: evidence from

two US population based cross sectionalsurveys of ageing. BMJ. 2010;340:c810.

Lindau ST et al. A study of sexuality and health among older adults in the United States. N Engl J Med.

2007;357:762.

Kinsey A et al. Age and sexual outlet. In: Kinsey A et al, eds. Sexual Behavior in the Human Male.

Philadelphia, PA: WB Saunders; 1984:218.

Starr BD, Weiner MB. The Star-Weiner Report on Sex and Sexuality in the Mature Years . New York, NY:

Stein and Day; 1981.

Persson G. Sexuality in a 70-year-old urban population. J Psychosom Res. 1980;24:335.

Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry.

1998;155:1310.

Vermeulen A, Kaufman JM. Ageing of the hypothalamopituitary-testicular axis in men. Horm Res. 1995;43:25.

Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male

Aging Study. J Urol. 1994;151:54.

Melman A. Evaluation of the first 70 patients in the center for male sexual dysfunction of Beth Israel Medical

Center. J Urol. 1984;131:53.

Mulligan T, Katz PG. Why aged men become impotent. Arch Intern Med. 1989;149:1365.

Hsueh WA. Sexual dysfunction with aging and systemic hypertension. Am J Cardiol. 1988;61:18H.

Padam-Nathan H et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated

Urethral System for Erection (MUSE) Study Group. N EnglJ Med. 1997;336:1.

Foster SA et al. Erectile dysfunction with or without coexisting benign prostatic hyperplasia in the general US

population: analysis of US National Health and Wellness Survey. Curr Med Res Opin. 2013;29(12):1709–1717.

Ayta IA et al. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible

policy consequences. BJU Int. 1999;84:50.

Krane RJ et al. Impotence. N EnglJ Med. 1989;321:1648.

Lue TF. Male sexual dysfunction. In: Tanagho E, McAninch J, eds. Smith’s General Urology. 13th ed. East

Norwalk, CT: Appleton & Lange; 1992:696.

Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

162.

163.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

183.

184.

.

activity. J Clin Endocrinol Metab. 1984;59:955.

Wein AJ, Van Arsdalen KN. Drug-induced male sexual dysfunction. Urol Clin North Am. 1988;15:23.

Bohlen JG et al. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch Intern

Med. 1984;144:1745.

Drory Y et al. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol.

1995;75:835.

Johnston BL, Fletcher GF. Dynamic electrocardiographic recording during sexual activity in recent postmyocardial infarction and revascularization patients. Am Heart J. 1979;98:736.

Jackson G. Sexual intercourse and angina pectoris. Int Rehabil Med. 1981;3:35.

Muller JE et al. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular

physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA. 1996;275:1405.

Ueno M. The so-called coition death [in Japanese]. Nihon Hoigaku Zasshi. 1963;17:330.

Meuleman E. Prevelance of erectile dysfunction: need for treatment? Int J Impot Res. 2002;14(Suppl 1):S22.

Goldstein I. Male sexual circuitry. Working Group for the Study of Central Mechanisms in Erectile Dysfunction.

Sci Am. 2000;283:70.

Gerstenberg TC, Bradley WE. Nerve conduction velocity measurement of dorsal nerve of penis in normal and

impotent males. Urology. 1983;21:90.

Whitehead ED et al. Diagnostic evaluation of impotence. Postgrad Med. 1990;88:123.

Spark RF et al. Impotence is not always psychogenic: newer insights into hypothalamic-pituitary-gonadal

dysfunction. JAMA. 1980;243:750.

Selvin E et al. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151.

Bancroft J, Wu FC. Changes in erectile responsiveness during androgen therapy. Arch Sex Behav. 1983;12:59.

Michal V et al. Arterial lesions in impotence: phalloarteriography. Int Angiol. 1984;3:247.

Bulpitt CJ, Dollery CT. Side effects of hypotensive agents evaluated by self-administered questionnaire. Br Med

J. 1973;3:485.

Bulpitt CJ, Fletcher AE. Drug treatment and quality of life in the elderly. Clin Geriatr Med. 1990;6:309.

Hogan MJ. Antihypertensive therapy and male sexual dysfunction. Psychosomatics. 1981;21:234.

Mallett EC, Badlani GH. Sexuality in the elderly. Semin Urol. 1987;5:141.

McWaine DE, Procci WR. Drug-induced sexual dysfunction. Med Toxicol Adverse Drug Exp. 1988;3:289.

Ebringer A et al. Clonidine in the treatment of hypertension. Br Med J. 1971;1:402.

Laver MC. Sexual behaviour patterns in male hypertensives. Aust N Z J Med. 1974;4:29.

Onesti G. Clonidine: a new antihypertensive agent. Am J Cardiol. 1971;28:74.

Mooradian AD et al. Hyperprolactinaemia in male diabetics. Postgrad Med J. 1985;61:11.

Burnett W. Sexual dysfunction as a complication of propranolol therapy in men. Cardiovasc Med. 1979;4:811.

Buffum J. Pharmacosexology: the effect of drugs on sexual function: a review. J Psychoactive Drugs.

1982;14:5.

Van Arsdalen KN, Wein AJ. Drug-induced sexual dysfunction in older men. Geriatrics. 1984;39:63.

Caine M. Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases. Urology. 1981;17:542.

Morley JE, Kaiser FE. Sexual function with advancing age. Med Clin North Am. 1989;73:1483.

McCellan KJ, Goa KL. Transdermal testosterone. Drugs. 1998;55:253.

Mirin SM et al. Opiate use and sexual function. Am J Psychiatry. 1980; 137:909.

Buffum JC. Pharmacosexology update: heroin and sexual function. J Psychoactive Drugs. 1983;15:317.

Beeley L. Drug-induced sexual dysfunction and infertility. Adverse Drug React Acute Poisoning Rev.

1984;3:23.

Rosen RC et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of

erectile dysfunction. Urology. 1997;49:822.

Rhoden EL et al. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool

to study the prevalance of erectile dysfunction. Int J Impot Res. 2002;14:245.

Jardin A et al, eds. Recommendations of the First International Consultation on Erectile Dysfunction,

cosponsored by the World Health Organization (WHO). Plymouth, England: Health Publications; 2000.

Wabrek AJ, Burchell RC. Male sexual dysfunction associated with coronary heart disease. Arch Sex Behav.

1980;9:69.

Gundle MJ et al. Psychosocial outcome after coronary artery surgery. Am J Psychiatry. 1980;137:1591.

Agarwal A, Jain DC. Male sexual dysfunction after stroke. J Assoc Physicians India. 1989;37:505.

Ruzbarsky V, Michal V. Morphologic changes in the arterial bed of the penis with aging. Relationship to the

.

.

.

.

190.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

212.

.

.

.

.

.

.

pathogenesis of impotence. Invest Urol. 1977;15:194.

Bulpitt CJ et al. Changes in symptoms of hypertensive patients after referral to hospital clinic. Br Heart J.

1976;38:121.

[No authors listed]. Adverse reaction to bendroflumethiazide and propranolol for the treatment of mild

hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet.

1981;2:539.

[No authors listed]. Comparison of prazosin with hydralazine in patients receiving hydrochlorothiazide: a

randomized double blind clinical trial. Circulation. 1981;64:722.

Virag R et al. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet.

1985;1:181.

Wabrek AJ et al. Noninvasive penile arterial evaluation in 120 males with erectile dysfunction. Urology.

1983;22:230.

Condra M et al. Prevalence and significance of tobacco smoking in impotence. Urology. 1986;27:495.

Hirshkowitz M et al. Nocturnal penile tumescence in cigarette smokers with erectile dysfunction. Urology.

1992;39:101.

DePalma RG et al. A screening sequence for vasculogenic impotence. J Vasc Surg. 1987;5:228.

Zemel P. Sexual dysfunction in the diabetic patient with hypertension. Am J Cardiol. 1988;61:27H.

Rubin A, Babbott D. Impotence and diabetes mellitus. JAMA. 1958;168:498.

Whitehead ED, Klyde BJ. Diabetes-related impotence in the elderly. Clin Geriatr Med. 1990;6:771.

McCulloch DK et al. The prevalence of diabetic impotence. Diabetologia. 1980;18:279.

Kannel WB et al. The role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol.

1974;34:29.

Lehman TP, Jacobs JA. Etiology of diabetic impotence. Urology. 1983;129:291.

Morley JE, Kaiser FE. Testicular function in the aging male. In: Armbrecht HJ et al, eds. Endocrine Function

and Aging. New York, NY: Springer-Verlag; 1990:99.

Snyder PJ et al. Serum LH and FSH responses to synthetic gonadotropin-releasing hormone in normal men. J

Clin Endocrinol Metab. 1975;41:938.

Tenover JS et al. Decreased serum inhibin levels in normal elderly men: evidence for a decline in Sertoli cell

function with aging. J Clin Endocrinol Metab. 1988;67:455.

Kaiser FE et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc. 1988;36:511.

Skakkebaek NE et al. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double

blind controlled study. Clin Endocrinol (Oxf). 1981;14:49.

Bancroft J. Endocrinology of sexual function. Clin Obstet Gynaecol. 1980;7:253.

Davidson JM et al. Hormonal changes and sexual function 5 in aging men. J Clin Endocrinol Metab. 1983;57:71.

Morley JE. Impotence. Am J Med. 1986;80:897.

Bissada NK, Finkbeiner AE. Urologic manifestations of drug therapy. Urol Clin North Am. 1988;15:725.

Deamer RL, Thompson JF. The role of medications in geriatric sexual function. Clin Geriatr Med. 1991;7:95.

Rendell MS et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled

trial. Sildenafil Diabetes Study Group. JAMA. 1999;281:421.

Cheitlin MD et al. ACC/AHA Expert Consensus Document: use of sildenafil (Viagra) in patients with

cardiovascular disease. American College of Cardiology/American Heart Association [published correction

appears in J Am Coll Cardiol. 1999;34:1850]. J Am Coll Cardiol. 1999;33:273.

Giuliano F et al. Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population

of men, irrespective of age. BJU Int. 2005;95:110.

Tsertsvadze A et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a

systematic review and meta-analysis. Ann Intern Med. 2009;151:650.

Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group [published

correction appears in N EnglJ Med. 1998;339:59]. N EnglJ Med. 1998;538:1397.

Morales A et al. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J

Impot Res. 1998;10:69.

Mitka M. Viagra leads as rivals are moving up. JAMA. 1998;280:119.

Giuliano F et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the

postmarketing safety database. Int J Clin Pract. 2010;64:240.

Cohen JS. Comparison of FDA reports of patient deaths associated with sildenafil and with injectable alprostadil.

Ann Pharmacother. 2001;35:285.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

233.

.

.

236.

.

.

239.

.

.

.

.

.

Arruda-Olson AM et al. Cardiovascular effects of sildenafil during exercise in men with known or probable

coronary artery disease. A randomized crossover trial. JAMA. 2002;287:719.

Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf.

2009;32:1.

Sadovsky R et al. Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract.

2001;55:115.

Angulo J et al. Tadalafil enhances NO-mediated relaxation of human arterial and trabecular penile smooth

muscle [abstract]. Annual Meeting of the European Association for the Study of Diabetes. Glasgow, Scotland;

2001.

Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in

patients with diabetes mellitus. Int J Impot Res. 2002;14:466.

Frajese GV et al. Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. Clin

Interv Aging. 2006;1:439.

Porst H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor,

in patients with erectile dysfunction: the first at home clinical trial. Int J Impot Res. 2001;13:192.

Steidle CP et al. Pharmacokientics of vardenafil in the elderly and subgroup data on efficacy and safety in

elderly patients with erectile dysfunction [abstract]. J Am Geriatr Soc. 2001;49:S103.

Thandani U et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the

treatment or erectile dysfunction, on the cardiovascular response to exercise in patients with coronary disease. J

Am Coll Cardiol. 2002;40:2006.

Hellstrom WJ et al. A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of

avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. BJU Int.

2013;111(1):137–147.

Whitehead ED et al. Treatment alternatives for impotence. Postgrad Med. 1990;88:139.

Carani C et al. The effects of testosterone administration and visual erotic stimuli on nocturnal penile

tumescence in normal men. Horm Behav. 1990;24:435.

Guay AT et al. Efficacy and safety of sildenafil for treatment of erectile dysfunction in a population with

associated organic risk factors [published correction appears in J Androl. 2002;23:113]. J Androl. 2001;22:793.

Yu Z et al. Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at

different sites of application and at the first and fifth days of application. J Clin Pharmacol. 1997;37:1129.

Winters SJ. Current status of testosterone replacement therapy in men. Arch Fam Med. 1999;8:257.

Parker S, Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal men.

Clin Endocrinol (Oxf). 1999;50:57.

Gann PH et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst.

1996;88:1118.